title: Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction.
abstract: At 12 centers, 395 patients, including 288 men (73%) and 107 women (27%) with acute myocardial infarction (AMI), were prospectively randomized to treatment with tissue plasminogen activator (t-PA) or primary percutaneous transluminal coronary angioplasty (PTCA). Compared with men, women were older (65.7 vs 57.7 years, p < 0.0001), more often had diabetes mellitus (19% vs 10%, p = 0.03), systemic hypertension (54% vs 39%, p = 0.005), prior congestive heart failure (5% vs 0%, p = 0.002), and presented later after symptom onset (229 vs 174 minutes, p = 0.0004). The in-hospital mortality in women was 3.3-fold higher than men (9.3% vs 2.8%, p = 0.005). After adjustment for comorbid baseline characteristics, however, only advanced age independently correlated with mortality. Among t-PA-treated patients, mortality was significantly higher in women than in men (14.0% vs 3.5%, p = 0.006). Intracranial hemorrhage after t-PA was also more common in women than in men (5.3% vs 0.7%, p = 0.037). In contrast, women and men had similar in-hospital mortality after primary PTCA (4.0% vs 2.1%, respectively, p = 0.46). No intracranial bleeding occurred in PTCA-treated patients. A univariate trend was present for reduced in-hospital mortality in women treated with PTCA rather than t-PA (4.0% vs 14.0%, p = 0.07). By multiple logistic regression analysis of 15 clinical variables, treatment with PTCA rather than t-PA, as well as younger age, were independently predictive of in-hospital survival in women.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cardiovascular Institute, El Camino Hospital, Mountain View, California 94040, USA.
authors.forename: G W
authors.initials: GW
authors.lastname: Stone
authors.forename: C L
authors.initials: CL
authors.lastname: Grines
authors.forename: K F
authors.initials: KF
authors.lastname: Browne
authors.forename: J
authors.initials: J
authors.lastname: Marco
authors.forename: D
authors.initials: D
authors.lastname: Rothbaum
authors.forename: J
authors.initials: J
authors.lastname: O'Keefe
authors.forename: G O
authors.initials: GO
authors.lastname: Hartzler
authors.forename: P
authors.initials: P
authors.lastname: Overlie
authors.forename: B
authors.initials: B
authors.lastname: Donohue
authors.forename: N
authors.initials: N
authors.lastname: Chelliah
mesh_terms: D000367:Age Factors; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D005260:Female; D006760:Hospitalization; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D012737:Sex Factors; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
chemical_list: D010959:Tissue Plasminogen Activator